We have generated transgenic mice expressing the human apolipoprotein CII (apoCII) gene under the transcriptional control of the human cytochrome P-450 IA1 (CYPIA1) promoter. Human apoCII transgenic (HuCIITg) mice exhibited significant basal expression of the transgene (plasma apoCII level = 26.1 +/-4 mg/dl) and showed further induction of transgene expression after treatment with beta-naphthoflavone. Unexpectedly, HuCIITg mice were hypertriglyceridemic and human apoCII levels correlated strongly to triglyceride levels (R = 0.89, P < 0.0001). Triglyceride levels (mg/dl +/-SEM) were elevated compared to controls in both the fed (804 +/-113 vs 146 +/-18, P < 0.001) and fasted (273 +/-39 vs 61 +/-4, P < 0.001) states. HuCIITg mice accumulated triglyceride-rich very low density lipoproteins (VLDL) with an increased apoC/apoE ratio. Tracer kinetic studies indicated delayed clearance of VLDL-triglyceride, and studies using Triton inhibition of VLDL clearance showed no increase in VLDL production. Plasma from these mice activated mouse lipoprotein lipase normally and radiolabeled VLDL were normally hydrolyzed. However, HuCIITg VLDL showed markedly decreased binding to heparin-Sepharose, suggesting that apoCII-rich, apoE-poor lipoprotein may be less accessible to cell surface lipases or receptors within their glycosaminoglycan matrices. HuCIITg mice are a promising model of hypertriglyceridemia that suggests a more complex role for apoCII in the metabolism of plasma triglycerides. 
Introduction
C apolipoproteins have both unique and overlapping functions in the metabolism oftriglyceride-rich lipoproteins. ApoCII has a central role in the trafficking of plasma triglyceride. It is the specific physiological activator oflipoprotein lipase (LPL) ' ( 1, 2) . Homozygous hereditary deficiency of apoCII leads to a hyperchylomicronemic syndrome very similar to hereditary LPL deficiency (3) (4) (5) . The heterozygous state for one mutant apoCII allele, when associated with apolipoprotein E4, also is associated with hypertriglyceridemia (6) . ApoCII, along with apoCl and apoCIII, interferes with the apoE-mediated removal of both chylomicrons and very low density lipoproteins (VLDL) by the perfused rat liver (7, 8) . ApoCI and apoCII inhibit apoE-mediated binding of rabbit fl-migrating VLDL to the low density lipoprotein receptor-related protein, a potential remnant receptor (9) . Transgenic mice expressing human apoCI are mildly hypertriglyceridemic, supporting the postulated role for apoCI in remnant clearance ( 10) . Transgenic mice overexpressing apoCIII are severely hypertriglyceridemic and show delayed VLDL clearance (1 1-12) .
To further explore the role ofthe C apolipoproteins in lipoprotein metabolism, we attempted to create a human apoCII transgenic mouse. An initial construction using the native apo-CII gene and its liver-specific enhancer ( 13) produced no transgenic mice. Because of concern that overexpression of apoCII may have caused the intrauterine death of transgenic fetuses, we redesigned the construction using the cytochrome P-450 IA1 (CYPIA 1 ) promoter, which is normally silent in intrauterine life. CYPIA1 is a xenobiotic-inducible gene expressed to a limited degree in many tissues but primarily in liver and proximal small intestine. The basal level of expression of the gene is very low. A variety of polycyclic aryl hydrocarbons have been shown to induce the gene including 3-methylcholanthrene and benz [a] anthracene ( 14) . ,B-naphthoflavone (,BNF) is a relatively nontoxic agent that has been widely used for induction of CYPIA1 gene expression and was therefore chosen for induction of expression of the transgene ( 15) . We now report the successful generation of transgenic mice with regulatable hepatic and intestinal expression ofthe transgene. We also report the unexpected observation of marked hypertriglyceridemia, with accumulation of triglyceride-enriched VLDL in the plasma of human apoCII transgenic mice.
Methods
Plasmid construction. Standard recombinant DNA techniques were tion, 202 bp into CYPIAl intron I. The insert of 1604.CAT was cloned into the HindIll site of pG9k, a modification of pGEM9zf(-) (Promega Corp., Madison, WI) with the NotI site converted to a KpnI site., creating pG9k450. Cosmid 20 containing the human apoCII gene and downstream sequences was the generous gift of Marten Hofker, University of Leiden (Leiden, The Netherlands) ( 17) . A 6-kb fragment was isolated extending from a unique BspEI site present -4 bp to the transcription initiation site of apoCII to a HindIll site 3.5 kb 3' to the gene and was blunt-end ligated into the NsiI site of pG9k450. The resulting clone, p450CII, was sequenced by the dideoxynucleotide method across all junctions to establish the correct orientation of the CYPIAI promoter and apoCII gene inserts. The entire apoCIl coding sequence of p450CII was sequenced to exclude the possibility ofmutation during cloning. Plasmids were prepared by alkaline lysis and banded twice through cesium chloride-ethidium bromide gradients.
Transgenic mice. The insert ofp450CII was obtained by KpnI/Sal I digestion and 0.7% agarose gel electrophoresis. DNA was extracted from the gel using Qiaex resin (Qiagen, Inc., Chatsworth, CA) and further purified on an Elutip column (Schleicher & Schuell, Inc., Keene, NH). Transgenic mice were created as previously described ( 18) . The fertilized eggs microinjected with the DNA construction were (C57B1/6J X CBA/J)F,. Integration of the human apoCII gene was determined by Southern blotting of tail-derived DNA. Gel-purified insert of a previously described apoClI cDNA, pCII-7 11, was labeled by the random-primed oligonucleotide technique and used as a probe (19, 20 Fig. 3 ) were drawn at 9 a.m., with food removed the previous 6 p.m. Fasting bloods cited in all other tables and figures were drawn at 5 p.m., 9 h after the removal of food. Postprandial ("fed") bloods were drawn at 9 a.m. Animals were anesthetized with methoxyflurane for retroorbital phlebotomy and intravenous femoral injections.
Promoter induction. CYPIA1 promoter induction was performed by intraperitoneal injection of a sonicated suspension of 14 mg/ml f-naphthoflavone in corn oil. 60 Ml of this suspension was used for induction before the RNase protection assay. 200 ,l of the suspension, containing -180 mg of triglyceride and equivalent to -130 mg/kg of f-naphthoflavone (about three times the dose effective in rats) was empirically found to induce protein expression and was used for induction in other experiments (22) . Control injections were performed with the corn oil vehicle. Injections were performed 9 h before "fasting" bloods and 12 h before "fed" bloods, and they were well-tolerated by the animals.
RNase protection assay. The apoCII RNA probe was derived by cloning the 500-bp PstI insert from pCII-7 1 1 into pGEM 1 (Promega Corp.) Orientation was determined by restriction digestion. RNase protection assay was performed as described on 10 Mg of total RNA extracted from the tissues of male high expressing animals (23) . The gels were scanned using laser densitometer (Ultroscan XL; LKB Instruments, Inc., Gaithersburg, MD).
Lipoprotein analysis. Triglyceride and cholesterol concentrations were performed using commercial kits (no. 126012 and no. 236691, respectively; Boehringer Mannheim Corp., Indianapolis, IN). Phospholipids were determined as total phosphorus (24 (25) . Each fraction was reisolated from a second ultracentrifugation at the same density before analysis. Protein concentrations in lipoprotein fractions were determined by the method of Lowry et al. with bovine serum albumin as the standard (26) . Gel filtration chromatography was performed on 200 gl of pooled mouse plasma using two Superose 6 columns in series (FPLC; Pharmacia Fine Chemicals, Piscataway, NJ). 40 0.5-ml fractions were collected and assayed for cholesterol and triglyceride.
Apolipoprotein CII quantitation. Human apoCII levels in mouse plasma were determined by rocket immunoelectrophoresis using a goat polyclonal antiserum to human apoCII (without cross-reactivity to normal mouse plasma) and a purified human apoCIl standard (Daiichi Pure Chemicals, Tokyo, Japan), as described for apoCIII ( 12) .
Apolipoprotein composition. VLDL total protein was quantitated by the method of Lowry (26) . To identify apolipoproteins, 5 jig of VLDL protein was isolated by a single ultracentrifugation to minimize losses of small apolipoproteins and analyzed by 3-15% gradient SDS-PAGE (27) . After staining in 45% methanol, 10% acetic acid, 0.1%
Coomassie blue R and destaining in 30% methanol, 10% acetic acid, the gels were scanned using a laser densitometer (Ultroscan XL; LKB Instruments, Inc.), and the apoE/apoC ratio was calculated. Preparation oflabeled VLDL. Triglyceride-labeled VLDL was produced by minor modification of a described protocol (12 50 ,g protein/ml in 100 mM Tris, 100 mM NaCl, 2 mM CaC12, and 0.2 g/dl BSA, pH 7.4, were incubated for 2 h at 37°C with an equal volume (0.5 ml) of heparin-Sepharose gel, preswollen in the same buffer. The buffer was removed and the gel was washed three times with fresh buffer. An equal volume of buffer containing 100 U/ml of heparin was added and incubated at 37°C for 10 min. The buffer was removed and the 3H remaining in the gel, heparin eluate, and initial buffer was determined. The experiment was performed in triplicate for each preparation.
Results
Human apoCII gene sequences beginning at -4 bp relative to the start of transcription and extending 3.5 kb 3' to the gene were joined to the human CYPIA1 promoter (Fig. 1) . The resulting DNA construction was microinjected into fertilized mouse eggs. Pups were screened by Southern blot and a transgenic founder was identified. All further studies were done on the progeny of this mouse.
Expression of the apoCII transgene at the RNA level was documented by RNase protection assay (Fig. 2) . In the noninduced state, expression of the human apoCII gene was demonstrated in brain and liver along with a very low level of proximal-intestinal expression. After induction with jNF, brain expression decreased by 43% and liver expression increased (31) . ApoCII levels were highly correlated with plasma triglyceride (R = 0.89 and P < 0.0001, Fig. 3 ). Mean triglyceride levels were 283±40 in transgenics vs 130±14 in controls (P < 0.05).
With day-period fasting, which was used in the subsequent experiments, noninduced HuCIITg mice showed a degree of hypertriglyceridemia similar to the overnight-fasted values. Triglyceride values increased markedly with feeding. Transgenic mice had an approximately fivefold increase in plasma triglyceride compared to controls in both the fasted and fed states. Fasting triglyceride levels were 273±39 (range = 99-635) vs 61±4 in controls (P < 0.001) . In the fed state, the mean triglyceride level in transgenics increased to 804±113 (range = 264-1746) vs 146±18 in controls (P < 0.001 fed transgenics vs controls and P < 0.0001 fed vs fasted transgenics).
JNF induction increased the apoCII protein and triglyceride levels in the fasted state (Table I) . Human apoCII levels after day-period fasting were 26.1±4 mg/dl (higher than after the nocturnal fast) and increased to 38.3±1 after ,BNF induction (P < 0.03). As the inducer was administered in corn oil, some increase in triglycerides was observed with the vehicle alone. Statistical comparisons of triglyceride levels were made between inducer and vehicle injections. After promoter induction in transgenic mice there was a 66% increase in fasting triglycerides vs the levels in the same mice after the injection of vehicle alone. This was statistically significant at P < 0.001. A small increase in fasting triglyceride levels after injection ofthe JNF suspension into control mice was not statistically significant. Cholesterol levels in transgenics were moderately higher than controls, whether noninduced (P < 0.05) or induced (P < 0.001). Cholesterol levels in transgenic mice after induction were significantly higher than in the noninduced state (P <0.001).
Gel filtration chromatography was performed on pooled plasma from 10 extent than triglyceride), slightly elevated in IDL + LDL and unchanged in HDL (Fig. 4) . Sequential density ultracentrifugation was also performed using pooled plasma from 5 HuCIITg mice and 15 controls with compositional analysis of lipoprotein fractions (Table II) . There was a marked increase in VLDL triglyceride levels in HuCIITg mice. VLDL cholesterol increased to a lesser degree and the VLDL cholesterol /triglyceride ratio was lower in HuCIITg mice and < 0.05. The elevation oftriglyceride relative to cholesterol, phospholipid and protein is suggestive of a predominance of large VLDL particles. IDL + LDL fractions were similar. An increase in HDL total protein/phospholipid ratio was noted in HuCIITg mice. Similar results were obtained from another pooled sample that did not undergo ultracentrifugal reisolation of lipoprotein fractions. A higher VLDL protein and an increased recovery of HDL were noted in the singly-spun pool, as would be expected as a result of lower purity and decreased losses in preparation. We further characterized the hypertriglyceridemic phenotype by analyzing apolipoprotein compositional changes. SDS-PAGE was performed on ultracentrifugally isolated Chylos + VLDL from control, HuCIITg, and HuCIITg,NF-induced mice in both the fed and fasted states (Fig. 5) Human Apo CII (mg/di) Figure 3 . Correlation of triglyceride and human apoCII levels after overnight fasting in HuCIITg mice, noninduced. The blood samples used for the correlation of human apoCII level and triglyceride were drawn at 9 a.m., with food removed the previous 6 p.m. Triglyceride levels were elevated and highly correlated to the human apoCII levels, as indicated.
after induction and, in the fed state, became barely detectable. ApoC/apoE ratios, as quantitated by laser densitometry, confirmed the marked decrease in apoE relative to apoC. In the fed state, the apoC/apoE ratio increased from 0.43 in controls to 6.94 in transgenics, and to 30.3 in transgenics after induction.
SDS-PAGE of HDL and IDL/LDL (data not shown) did not
show an increase in apoC or other change in apolipoprotein relative composition. To shed light on the mechanism of hypertriglyceridemia in these animals, we assessed the relative contributions of overproduction and decreased clearance of VLDL triglyceride by performing turnover studies using in vivo-labeled control VLDL. Similar preparations have been shown to take on the characteristics of the plasma milieu into which they are infused, presumably via rapid apolipoprotein exchange (12) . Both transgenic and control mice were, therefore, studied with the same preparations, isolated from control mice. In the animals used in the turnover studies, triglyceride levels (mean±SD) were 371±279 in transgenics and 135.5±34.4 in controls. Calculated fractional catabolic rates in pools/ hour±SD were 3.5±3.6 in transgenics vs 17.7±12.6 in controls (P < 0.02), pointing to a clearance defect in the transgenic animals. Figure 5 . SDS-PAGE with 3-15% polyacrylamide gradient. Lanes 1 and 10 contain low molecular weight SDS-PAGE standards (Pharmacia Fine Chemicals); their molecular weight in kilodaltons appears on the left side of the figure. Lanes 2, 3, and 4 contain VLDL/chylomicrons from the fed state from control, HuCIITg mice, and postinduction HuCIITg mice, respectively. Lanes 5-7 are in the same order and reflect the fasted state. Lane 8 is purified human apoCII and lane 9 purified human apoE. The location ofapoB100, apoB48, apoE, and apoCII/apoCIII is indicated on the right side ofthe figure. The apoBlOO/apoB48 ratios are approximately constant and consistent, in mice, with a predominant hepatic origin of triglyceride-rich lipoproteins. The apoCIl/CIiI band is increased in HuCIITg mouse VLDL. The apoE band is dramatically decreased and, in the fed state, decreases further after transgene promoter induction with OlNF. tion rates as measured by this technique were (mean±SD) 0.085±0.037 mg/h * g in controls vs 0.062±0.061 mg/h g in HuCIITg mice, a nonsignificant difference. Clearly, by both techniques, overproduction of triglyceride-rich particles did not appear to play a role in the etiology of HuCIITg hypertriglyceridemia.
To better define the mechanism of the observed catabolic defect, we assessed the ability ofplasma from HuCIITg mice to activate LPL. Lipase assays were performed using both control and HuCIITg plasma to activate partially purified mouse LPL. The mouse enzyme was used because ofthe possibility ofinterspecies incompatibility between human apoCII and mouse LPL. As shown in Fig. 6 , varying amounts ofplasma from both control and HuCIITg mice produced similar activation of lipolysis over a wide range of activity. Studies were also performed using purified in vivo-labeled VLDL from control or HuCIITg mice as the substrate (data not shown). No difference was seen in the triglyceride hydrolysis of the two preparations in a solution assay.
Finally, VLDL binding to heparin-Sepharose was assessed using control and HuCIITg VLDL preparations. There was approximately fourfold greater adherence of control VLDL vs HuCIITg VLDL to this gel (Fig. 7) , a model for the cell surface glycosaminoglycan matrix. Both heparin-releasable (P = 0.006) and non-heparin-releasable (P = 0.00 13) binding of transgenic VLDL were significantly decreased.
Discussion
In the present study, we report the creation of a human apoCII transgenic mouse using the CYPIA 1 promoter, a novel system for the regulatable expression of a transgene. The CYPIA 1 promoter was chosen because of its high degree of inducibility and lack of constitutive expression in mice during intrauterine life (32 (33) . Genetic differences among the mice studied and the presence of trace inducers in the environment may have accounted for the variability in expression of human apoCI.
The association of overexpression of apoCII, the cofactor for the hydrolysis of triglyceride by LPL, with hypertriglyceridemia in transgenic mice was unexpected. Our studies indicated a catabolic defect, which might have been present at the level of either particle clearance or lipolysis. All three C apolipoproteins have been shown to interfere with the apoE-mediated hepatic uptake of triglyceride-rich particles (7, 8, 34) , and apoCI and apoCII interfere significantly with the binding of d-migrating VLDL to lipoprotein receptor-related protein (9) . However, ifexcess apoCII in HuCIITg mice were acting by interfering with remnant clearance, through the observed decrease in VLDL apoE, a greater elevation ofplasma cholesterol would have been anticipated. Transgenic mice expressing a mutant human apoE defective in both receptor and heparin binding are hypertriglyceridemic and hypercholesterolemic with cholesterol enrichment of VLDL despite the absence of plasma cholesteryl-ester transfer protein activity in this species (35) . ApoE-null mice are severely hypercholesterolemic with only minimal elevation of triglyceride (36, 37 (38) , while apoE has been shown to increase the binding and enhance the hydrolysis of a triglyceride emulsion by heparin-Sepharose-bound LPL (39) . ApoE also enhanced lipolysis of emulsions by hepatic lipase bound to heparin-Sepharose, an effect opposed by both apoCII and apoCIII (40) . In vivo, apoE could facilitate access of lipoprotein particles to the negatively charged glycosaminoglycan matrix, where cell surface lipases reside. Proteoglycan interaction with apoE has also been shown to be important in facilitating receptor-mediated lipoprotein binding and uptake by cells (41 ) . Nevertheless, the apparent displacement of apoE by apoCII, as would have been expected (8), does not establish an etiologic role for decreased VLDL apoE in the observed hypertriglyceridemia. In fact, it has been suggested that certain newly-secreted VLDL lack apoE and require lipolysis before they will bind apoE to any significant degree (42) . Decreased VLDL apoE may be a marker ofexcess apoCII binding rather than a mediator of defective lipolysis in HuCIITg mice. Indeed, the absence of significant hypertriglyceridemia in the extreme case oftotal apoE deficiency, as seen in apoE null mice, argues against the importance of any apoE-related mechanism in HuCIITg mice (36). Excess apoCII may itself be interfering with the association of triglyceride-rich lipoproteins with glycosaminoglycans in HuCIITg mice, as has been shown for both apoCII and apoCIII in vitro (40) . This could impair either lipolysis or particle clearance. Our data show that HuCIITg VLDL is defective in its interaction with heparin-Sepharose. We postulate that a similar defect may occur at the cell surface in the interaction of VLDL with cell surface lipases or receptors. Whether this is caused by excess apoCII, decreased apoE, or both remains unanswered.
All three C apolipoproteins may, in some respects, play similar roles. ApoCI and apoCII Human apoCI transgenic mice are known to be hypertriglyceridemic ( 10) as are HuCIIITg mice ( 12) . The correlation between levels of apoCIII and triglyceride levels in HuCIIITg mice appears similar to that of apoCII and triglyceride in HuCIITg mice ( 12) . This holds true, despite the fact that apoCI and apoCIII inhibit lipoprotein lipase activity in solution assays, at levels where apoCII remains an activator ( 1, 2, 43) . Moreover, VLDL from HuCIIITg and HuCIITg mice are compositionally similar and, in kinetic studies, show a decreased fractional catabolic rate for triglyceride without an increase in production rate. There is also normal hydrolysis of HuCIIITg VLDL by LPL in a solution assay ( 12) .
HuCIITg mice are a potentially instructive model ofhypertriglyceridemia and raise the possibility that overexpression of apoCII may have a role in human disease. Future experiments will further address the role ofC apolipoproteins in the interaction oftriglyceride-rich lipoproteins with lipoprotein receptors, LPL, and hepatic lipase at the cell surface and within glycosaminoglycan matrices.
